Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.

Breitkreutz I, Podar K, Figueroa-Vazquez V, Wilhelm S, Hayden PJ, Anderson KC, Raab MS.

Ann Hematol. 2018 May;97(5):839-849. doi: 10.1007/s00277-018-3237-5. Epub 2018 Jan 23.

PMID:
29359239
2.

A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma.

Vallet S, Hoyle NR, Kyle RA, Podar K, Pecherstorfer M.

Leuk Lymphoma. 2018 Jan 18:1-8. doi: 10.1080/10428194.2017.1421757. [Epub ahead of print]

PMID:
29345175
3.

Editorial: Multiple Myeloma Immunotherapies.

Podar K.

Curr Cancer Drug Targets. 2017;17(9):768. doi: 10.2174/156800961709171005160041. No abstract available.

PMID:
29117857
4.

Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming.

Bhanot H, Weisberg EL, Reddy MM, Nonami A, Neuberg D, Stone RM, Podar K, Salgia R, Griffin JD, Sattler M.

Oncotarget. 2017 Jun 28;8(40):67639-67650. doi: 10.18632/oncotarget.18797. eCollection 2017 Sep 15.

5.

Adoptive cell therapy in multiple Myeloma.

Vallet S, Pecherstorfer M, Podar K.

Expert Opin Biol Ther. 2017 Dec;17(12):1511-1522. doi: 10.1080/14712598.2017.1375095. Epub 2017 Sep 6. Review.

PMID:
28857616
6.

Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.

Podar K, Pecherstorfer M.

Expert Opin Pharmacother. 2017 Aug;18(11):1061-1079. doi: 10.1080/14656566.2017.1340942. Epub 2017 Jul 5. Review.

PMID:
28604120
7.

Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.

Podar K, Jager D.

Curr Cancer Drug Targets. 2017;17(9):782-805. doi: 10.2174/1568009617666170214103834.

PMID:
28201977
8.

The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment.

Fan F, Bashari MH, Morelli E, Tonon G, Malvestiti S, Vallet S, Jarahian M, Seckinger A, Hose D, Bakiri L, Sun C, Hu Y, Ball CR, Glimm H, Sattler M, Goldschmidt H, Wagner EF, Tassone P, Jaeger D, Podar K.

Leukemia. 2017 Jul;31(7):1570-1581. doi: 10.1038/leu.2016.358. Epub 2016 Nov 28.

PMID:
27890927
9.

Targeting the Bone Marrow Microenvironment.

Moschetta M, Kawano Y, Podar K.

Cancer Treat Res. 2016;169:63-102. Review.

PMID:
27696259
10.

Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET Pathway.

Vallet S, Bashari MH, Fan FJ, Malvestiti S, Schneeweiss A, Wuchter P, Jäger D, Podar K.

PLoS One. 2016 Mar 2;11(3):e0150507. doi: 10.1371/journal.pone.0150507. eCollection 2016.

11.

Prolyl Hydroxylase 3 Attenuates MCL-1-Mediated ATP Production to Suppress the Metastatic Potential of Colorectal Cancer Cells.

Radhakrishnan P, Ruh N, Harnoss JM, Kiss J, Mollenhauer M, Scherr AL, Platzer LK, Schmidt T, Podar K, Opferman JT, Weitz J, Schulze-Bergkamen H, Koehler BC, Ulrich A, Schneider M.

Cancer Res. 2016 Apr 15;76(8):2219-30. doi: 10.1158/0008-5472.CAN-15-1474. Epub 2016 Feb 26.

12.

Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.

Bashari MH, Fan F, Vallet S, Sattler M, Arn M, Luckner-Minden C, Schulze-Bergkamen H, Zörnig I, Marme F, Schneeweiss A, Cardone MH, Opferman JT, Jäger D, Podar K.

Breast Cancer Res. 2016 Feb 26;18(1):26. doi: 10.1186/s13058-016-0686-4.

13.

Toward optimizing pomalidomide therapy in MM patients.

Podar K.

Blood. 2015 Jun 25;125(26):3968-9. doi: 10.1182/blood-2015-05-641746.

14.

Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells.

Bhanot H, Reddy MM, Nonami A, Weisberg EL, Bonal D, Kirschmeier PT, Salgia S, Podar K, Galinsky I, Chowdary TK, Neuberg D, Tonon G, Stone RM, Asara J, Griffin JD, Sattler M.

Leukemia. 2015 Jul;29(7):1555-1563. doi: 10.1038/leu.2015.46. Epub 2015 Feb 23.

15.

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.

Wagner V, Hose D, Seckinger A, Weiz L, Meißner T, Rème T, Breitkreutz I, Podar K, Ho AD, Goldschmidt H, Krämer A, Klein B, Raab MS.

Oncotarget. 2014 Nov 15;5(21):10237-50.

16.

Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.

Fan F, Tonon G, Bashari MH, Vallet S, Antonini E, Goldschmidt H, Schulze-Bergkamen H, Opferman JT, Sattler M, Anderson KC, Jäger D, Podar K.

Cancer Lett. 2014 Feb 28;343(2):286-94. doi: 10.1016/j.canlet.2013.09.042. Epub 2013 Oct 8.

PMID:
24120758
17.

New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.

Vallet S, Podar K.

Expert Opin Biol Ther. 2013 Jun;13 Suppl 1:S35-53. doi: 10.1517/14712598.2013.807337. Epub 2013 Jun 17. Review.

PMID:
23768134
18.

MM-associated anemia: more than "crowding out" HSPCs.

Podar K.

Blood. 2012 Sep 27;120(13):2539-40. No abstract available.

19.

GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo.

Raab MS, Breitkreutz I, Anderhub S, Rønnest MH, Leber B, Larsen TO, Weiz L, Konotop G, Hayden PJ, Podar K, Fruehauf J, Nissen F, Mier W, Haberkorn U, Ho AD, Goldschmidt H, Anderson KC, Clausen MH, Krämer A.

Cancer Res. 2012 Oct 15;72(20):5374-85. doi: 10.1158/0008-5472.CAN-12-2026. Epub 2012 Aug 31.

20.

Novel targets and derived small molecule inhibitors in multiple myeloma.

Podar K.

Curr Cancer Drug Targets. 2012 Sep;12(7):797-813. Review.

PMID:
22671928
21.

Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.

Vallet S, Witzens-Harig M, Jaeger D, Podar K.

Expert Opin Pharmacother. 2012 Mar;13(4):473-94. doi: 10.1517/14656566.2012.656091. Epub 2012 Feb 13. Review.

PMID:
22324734
22.

Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.

Podar K, Anderson KC.

Curr Cancer Drug Targets. 2011 Nov;11(9):1005-24. Review.

PMID:
21933109
23.

The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.

Podar K, Zimmerhackl A, Fulciniti M, Tonon G, Hainz U, Tai YT, Vallet S, Halama N, Jäger D, Olson DL, Sattler M, Chauhan D, Anderson KC.

Br J Haematol. 2011 Nov;155(4):438-48. doi: 10.1111/j.1365-2141.2011.08864.x. Epub 2011 Sep 19.

PMID:
21923653
24.

Targeting the tumor microenvironment: focus on angiogenesis.

Fan F, Schimming A, Jaeger D, Podar K.

J Oncol. 2012;2012:281261. doi: 10.1155/2012/281261. Epub 2011 Aug 24.

25.

Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.

Fernandes MS, Reddy MM, Croteau NJ, Walz C, Weisbach H, Podar K, Band H, Carroll M, Reiter A, Larson RA, Salgia R, Griffin JD, Sattler M.

J Biol Chem. 2010 Oct 15;285(42):32596-605. doi: 10.1074/jbc.M110.106161. Epub 2010 Jul 9.

26.

A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.

Podar K, Anderson KC.

Cell Cycle. 2010 May;9(9):1722-8. Epub 2010 May 1. Review.

27.

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.

Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, Burger P, Rumizen MJ, Podar K, Chauhan D, Hideshima T, Munshi NC, Richardson P, Clark A, Ogden J, Goutopoulos A, Rastelli L, Anderson KC, Tai YT.

Br J Haematol. 2010 May;149(4):537-49. doi: 10.1111/j.1365-2141.2010.08127.x. Epub 2010 Mar 12.

28.

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, Bianchi G, Podar K, Tai YT, Mitsiades C, Raje N, Jaye DL, Kumar SK, Richardson P, Munshi N, Anderson KC.

Cancer Cell. 2009 Oct 6;16(4):309-23. doi: 10.1016/j.ccr.2009.08.019.

29.

Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.

Blotta S, Tassone P, Prabhala RH, Tagliaferri P, Cervi D, Amin S, Jakubikova J, Tai YT, Podar K, Mitsiades CS, Zullo A, Franco B, Anderson KC, Munshi NC.

Blood. 2009 Oct 8;114(15):3276-84. doi: 10.1182/blood-2009-04-219436. Epub 2009 Jul 8.

30.

BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair.

Fernandes MS, Reddy MM, Gonneville JR, DeRoo SC, Podar K, Griffin JD, Weinstock DM, Sattler M.

Blood. 2009 Aug 27;114(9):1813-9. doi: 10.1182/blood-2008-07-172148. Epub 2009 Jul 1.

31.

Multiple myeloma.

Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC.

Lancet. 2009 Jul 25;374(9686):324-39. doi: 10.1016/S0140-6736(09)60221-X. Epub 2009 Jun 21. Review.

PMID:
19541364
32.

Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma.

Zhang J, Sattler M, Tonon G, Grabher C, Lababidi S, Zimmerhackl A, Raab MS, Vallet S, Zhou Y, Cartron MA, Hideshima T, Tai YT, Chauhan D, Anderson KC, Podar K.

Cancer Res. 2009 Jun 15;69(12):5082-90. doi: 10.1158/0008-5472.CAN-08-4603. Epub 2009 Jun 9.

33.

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.

Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC.

Blood. 2009 Jul 30;114(5):1046-52. doi: 10.1182/blood-2009-01-199604. Epub 2009 May 12.

34.

Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.

Hideshima T, Chauhan D, Kiziltepe T, Ikeda H, Okawa Y, Podar K, Raje N, Protopopov A, Munshi NC, Richardson PG, Carrasco RD, Anderson KC.

Blood. 2009 May 21;113(21):5228-36. doi: 10.1182/blood-2008-06-161505. Epub 2009 Mar 6.

35.

Emerging therapies for multiple myeloma.

Podar K, Tai YT, Hideshima T, Vallet S, Richardson PG, Anderson KC.

Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278 . Review.

36.

CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.

Tai YT, Soydan E, Song W, Fulciniti M, Kim K, Hong F, Li XF, Burger P, Rumizen MJ, Nahar S, Podar K, Hideshima T, Munshi NC, Tonon G, Carrasco RD, Afar DE, Anderson KC.

Blood. 2009 Apr 30;113(18):4309-18. doi: 10.1182/blood-2008-10-183772. Epub 2009 Feb 4. Erratum in: Blood. 2009 Sep 24;114(13):2852. Retraction in: Blood. 2010 Apr 8;115(14):2983.

37.

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.

Raje N, Hideshima T, Mukherjee S, Raab M, Vallet S, Chhetri S, Cirstea D, Pozzi S, Mitsiades C, Rooney M, Kiziltepe T, Podar K, Okawa Y, Ikeda H, Carrasco R, Richardson PG, Chauhan D, Munshi NC, Sharma S, Parikh H, Chabner B, Scadden D, Anderson KC.

Leukemia. 2009 May;23(5):961-70. doi: 10.1038/leu.2008.378. Epub 2009 Jan 8.

PMID:
19151776
38.

Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.

Burger R, Le Gouill S, Tai YT, Shringarpure R, Tassone P, Neri P, Podar K, Catley L, Hideshima T, Chauhan D, Caulder E, Neilan CL, Vaddi K, Li J, Gramatzki M, Fridman JS, Anderson KC.

Mol Cancer Ther. 2009 Jan;8(1):26-35. doi: 10.1158/1535-7163.MCT-08-0149.

39.

Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling.

Raab MS, Breitkreutz I, Tonon G, Zhang J, Hayden PJ, Nguyen T, Fruehauf JH, Lin BK, Chauhan D, Hideshima T, Munshi NC, Anderson KC, Podar K.

Blood. 2009 Feb 12;113(7):1513-21. doi: 10.1182/blood-2008-05-157040. Epub 2008 Nov 18.

40.

Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.

Song W, van der Vliet HJ, Tai YT, Prabhala R, Wang R, Podar K, Catley L, Shammas MA, Anderson KC, Balk SP, Exley MA, Munshi NC.

Clin Cancer Res. 2008 Nov 1;14(21):6955-62. doi: 10.1158/1078-0432.CCR-07-5290.

41.

Bone marrow microenvironment and the identification of new targets for myeloma therapy.

Podar K, Chauhan D, Anderson KC.

Leukemia. 2009 Jan;23(1):10-24. doi: 10.1038/leu.2008.259. Epub 2008 Oct 9. Review.

42.

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.

Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, Walz C, Reiter A, Podar K, Royer Y, Constantinescu SN, Tomasson MH, Griffin JD, Gilliland DG, Sattler M.

Blood. 2008 Apr 1;111(7):3751-9. doi: 10.1182/blood-2007-07-102186. Epub 2008 Jan 23.

43.

The malignant clone and the bone-marrow environment.

Podar K, Richardson PG, Hideshima T, Chauhan D, Anderson KC.

Best Pract Res Clin Haematol. 2007 Dec;20(4):597-612. Review.

PMID:
18070708
44.

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.

Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P, Munshi N, Palladino MA, Anderson KC.

Blood. 2008 Feb 1;111(3):1654-64. Epub 2007 Nov 15.

45.

The therapeutic role of targeting protein kinase C in solid and hematologic malignancies.

Podar K, Raab MS, Chauhan D, Anderson KC.

Expert Opin Investig Drugs. 2007 Oct;16(10):1693-707. Review.

PMID:
17922632
46.

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, van Abbema A, Jesaitis L, Caras I, Law D, Weller E, Xie W, Richardson P, Munshi NC, Mathiot C, Avet-Loiseau H, Afar DE, Anderson KC.

Blood. 2008 Aug 15;112(4):1329-37. Epub 2007 Sep 28.

47.

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.

Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, Ikeda H, Okawa Y, Hideshima H, Munshi NC, Yasui H, Richardson PG, Anderson KC.

Br J Haematol. 2007 Sep;138(6):783-91.

PMID:
17760810
48.

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S, Pozzi S, Breitkreutz I, Kiziltepe T, Yasui H, Ocio EM, Shiraishi N, Jin J, Okawa Y, Ikeda H, Mukherjee S, Vaghela N, Cirstea D, Ladetto M, Boccadoro M, Anderson KC.

Blood. 2007 Nov 15;110(10):3744-52. Epub 2007 Aug 22.

49.

A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.

Podar K, Gouill SL, Zhang J, Opferman JT, Zorn E, Tai YT, Hideshima T, Amiot M, Chauhan D, Harousseau JL, Anderson KC.

Oncogene. 2008 Jan 31;27(6):721-31. Epub 2007 Jul 23.

PMID:
17653083
50.

Inhibition of the TGF-beta signaling pathway in tumor cells.

Podar K, Raje N, Anderson KC.

Recent Results Cancer Res. 2007;172:77-97. Review. No abstract available.

PMID:
17607937

Supplemental Content

Support Center